CME Outfitters

10/19/2026

📊 Compare your treatment choices with experts, peers, patients—and AI insights.

See how evidence translates into practice in dynamic, case-based scenarios.
🔗 https://cmeo.me/MMV-162

Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into...

10/19/2026

🚨 Tomorrow!

Don't miss this live symposium designed for family medicine clinicians.

Discover practical approaches to:
🩺 eGFR and uACR screening
📈 KDIGO risk stratification
🤝 Shared decision-making
❤️ Integrated CKM management

📅 October 20 | 8:00 PM ET

👉 Register today: https://cmeo.me/MMS-166

Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, howev...

10/19/2026

🤝 Managing fibrosis requires a multidisciplinary approach.

Designed for gastroenterologists, GI fellows, NPs, PAs, nurses, and pharmacists, this podcast provides practical insights to support earlier recognition and personalized management of IBD-related fibrosis.

🎧 https://cmeo.me/PD-120

Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) car...

10/18/2026

💡 Not every promising trial signal tells the whole story.

What makes a result clinically meaningful? How should efficacy be balanced against tolerability? And how should clinicians think about variation in individual treatment response?

Explore these questions and more in the final Riding the Waves of Obesity Science conversation.

👉 https://cmeo.me/SN-317

The obesity pipeline is moving faster than the evidence can be absorbed. A new class of amylin-based agents — investigational therapies now advancing through phase 2 and phase 3 trials with several studied both on their...

10/18/2026

🔬 The MASH treatment landscape is evolving. Are you keeping up with the latest science?

FGF21 analogues are emerging as a promising investigational class targeting both metabolic dysfunction and fibrosis in patients with MASH.

Explore CME Outfitters' Snack, FGF21 Frontier in Clinically Significant MASH, to better understand FGF21 biology, emerging clinical evidence, and the potential role of this pathway in future treatment strategies.

🎥 Explore the activity: https://cmeo.me/SN-318

New therapies are reshaping care for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, yet compensated cirrhosis remains a frontier with no approved pharmacologic option. Fibroblast growth factor 21 (FGF21) analogues are a closely watched investigational...

10/17/2026

🚀 Take a more comprehensive approach to IBD care.

Gain practical insights into:
✔️ Recognizing high-impact EIMs
✔️ Integrating screening into clinical workflows
✔️ Coordinating multidisciplinary care
✔️ Supporting patients with systemic disease involvement

Listen now: https://cmeo.me/PD-121

Extraintestinal manifestations (EIMs) affect up to one-third of patients with inflammatory bowel disease (IBD) and can significantly contribute to morbidity, impaired quality of life, and long-term disease burden, yet they remain inconsistently recognized and managed in...

10/17/2026

🧠 What if the neuropathy in front of you isn't what it seems?

Chronic inflammatory demyelinating polyneuropathy (CIDP) can mimic other neuropathies, making timely and accurate diagnosis a challenge.

In CME Outfitters' recorded CaseWise™ webcast, explore realistic patient cases designed to strengthen diagnostic confidence and support evidence-based CIDP management.

🎥 Watch on demand: https://cmeo.me/WCV-157

What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP...

10/17/2026

🧠 Could you recognize generalized myasthenia gravis (gMG) early enough to make a difference?

With fluctuating muscle weakness and variable clinical presentations, timely recognition and accurate diagnosis of gMG can be challenging.

In CME Outfitters' recorded CaseWise™ webcast, explore real-world patient cases designed to strengthen diagnostic confidence and identify appropriate candidates for FcRn-directed therapy.

🎥 Watch on demand: https://cmeo.me/WCV-156

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease that can profoundly disrupt strength and independence through unpredictable, fluctuating muscle weakness. Recent advances have transformed the treatment landscape, with targeted therapies such as neonatal Fc...

10/17/2026

Food is foundational to health.

Join experts to explore how clinicians can champion food equity and reduce chronic disease risk in underserved populations.
🔗 https://cmeo.me/SN-249

Food insecurity and nutritional inequity disproportionately impact underserved communities. These disparities are directly linked to higher rates of chronic diseases, such as obesity, diabetes, and cardiovascular diseases. Research shows that access to healthy food is limited...

10/16/2026